Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics.

Petrasheskaya N, Tae HJ, Ahmet I, Talan MI, Lakatta EG, Lin L.

J Vis Exp. 2016 Sep 19;(115). doi: 10.3791/53777.

2.

Vessel ultrasound sonographic assessment of soluble receptor for advanced glycation end products efficacy in a rat balloon injury model.

Tae HJ, Petrashevskaya N, Ahmet I, Park S, Talan MI, Lakatta EG, Lin L.

Curr Ther Res Clin Exp. 2014 Nov 11;76:110-5. doi: 10.1016/j.curtheres.2014.08.001. eCollection 2014 Dec.

3.

The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth.

Tae HJ, Kim JM, Park S, Tomiya N, Li G, Wei W, Petrashevskaya N, Ahmet I, Pang J, Cruschwitz S, Riebe RA, Zhang Y, Morrell CH, Browe D, Lee YC, Xiao RP, Talan MI, Lakatta EG, Lin L.

J Mol Med (Berl). 2013 Dec;91(12):1369-81. doi: 10.1007/s00109-013-1091-4. Epub 2013 Oct 17.

4.

Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy.

Ahmet I, Tae HJ, Brines M, Cerami A, Lakatta EG, Talan MI.

J Pharmacol Exp Ther. 2013 Jun;345(3):446-56. doi: 10.1124/jpet.113.202945. Epub 2013 Apr 12.

5.

Myocardial infarction: cardioprotection by erythropoietin.

Talan MI, Latini R.

Methods Mol Biol. 2013;982:265-302. doi: 10.1007/978-1-62703-308-4_17.

6.

Acute hemodynamic effects of erythropoietin do not mediate its cardioprotective properties.

Ahmet I, Lakatta EG, Talan MI.

Biol Open. 2012 Oct 15;1(10):1049-53. doi: 10.1242/bio.20122378. Epub 2012 Aug 22.

7.

Chronic treatment with a broad-spectrum metalloproteinase inhibitor, doxycycline, prevents the development of spontaneous aortic lesions in a mouse model of vascular Ehlers-Danlos syndrome.

Tae HJ, Marshall S, Zhang J, Wang M, Briest W, Talan MI.

J Pharmacol Exp Ther. 2012 Oct;343(1):246-51. doi: 10.1124/jpet.112.197020. Epub 2012 Jul 19.

8.

Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window?

Talan MI, Ahmet I, Lakatta EG.

PLoS One. 2012;7(4):e34819. doi: 10.1371/journal.pone.0034819. Epub 2012 Apr 18.

9.

SRT1720 improves survival and healthspan of obese mice.

Minor RK, Baur JA, Gomes AP, Ward TM, Csiszar A, Mercken EM, Abdelmohsen K, Shin YK, Canto C, Scheibye-Knudsen M, Krawczyk M, Irusta PM, Martín-Montalvo A, Hubbard BP, Zhang Y, Lehrmann E, White AA, Price NL, Swindell WR, Pearson KJ, Becker KG, Bohr VA, Gorospe M, Egan JM, Talan MI, Auwerx J, Westphal CH, Ellis JL, Ungvari Z, Vlasuk GP, Elliott PJ, Sinclair DA, de Cabo R.

Sci Rep. 2011;1:70. doi: 10.1038/srep00070. Epub 2011 Aug 18. Erratum in: Sci Rep. 2013;3():1131.

10.

Fenoterol enantiomers do not possess beneficial therapeutic properties of their racemic mixture in the rat model of post myocardial infarction dilated cardiomyopathy.

Ahmet I, Turner T, Lakatta EG, Talan MI.

Cardiovasc Drugs Ther. 2012 Apr;26(2):101-8. doi: 10.1007/s10557-011-6366-9.

11.

Allele-specific siRNA knockdown as a personalized treatment strategy for vascular Ehlers-Danlos syndrome in human fibroblasts.

Müller GA, Hansen U, Xu Z, Griswold B, Talan MI, McDonnell NB, Briest W.

FASEB J. 2012 Feb;26(2):668-77. doi: 10.1096/fj.11-182162. Epub 2011 Oct 28.

12.

Effects of calorie restriction on cardioprotection and cardiovascular health.

Ahmet I, Tae HJ, de Cabo R, Lakatta EG, Talan MI.

J Mol Cell Cardiol. 2011 Aug;51(2):263-71. doi: 10.1016/j.yjmcc.2011.04.015. Epub 2011 May 14.

13.

Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome.

Briest W, Cooper TK, Tae HJ, Krawczyk M, McDonnell NB, Talan MI.

J Pharmacol Exp Ther. 2011 Jun;337(3):621-7. doi: 10.1124/jpet.110.177782. Epub 2011 Mar 1.

14.

A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.

Ahmet I, Tae HJ, Juhaszova M, Riordon DR, Boheler KR, Sollott SJ, Brines M, Cerami A, Lakatta EG, Talan MI.

Mol Med. 2011 Mar-Apr;17(3-4):194-200. doi: 10.2119/molmed.2010.00235. Epub 2010 Dec 16.

15.

Chronic alternate-day fasting results in reduced diastolic compliance and diminished systolic reserve in rats.

Ahmet I, Wan R, Mattson MP, Lakatta EG, Talan MI.

J Card Fail. 2010 Oct;16(10):843-53. doi: 10.1016/j.cardfail.2010.05.007. Epub 2010 Jul 1.

16.

β₂ AR agonists in treatment of chronic heart failure: long path to translation.

Talan MI, Ahmet I, Xiao RP, Lakatta EG.

J Mol Cell Cardiol. 2011 Oct;51(4):529-33. doi: 10.1016/j.yjmcc.2010.09.019. Epub 2010 Oct 1. Review.

17.

The haploinsufficient Col3a1 mouse as a model for vascular Ehlers-Danlos syndrome.

Cooper TK, Zhong Q, Krawczyk M, Tae HJ, Müller GA, Schubert R, Myers LA, Dietz HC, Talan MI, Briest W.

Vet Pathol. 2010 Nov;47(6):1028-39. doi: 10.1177/0300985810374842. Epub 2010 Jun 29.

19.

Cardioprotective and survival benefits of long-term combined therapy with beta2 adrenoreceptor (AR) agonist and beta1 AR blocker in dilated cardiomyopathy postmyocardial infarction.

Ahmet I, Krawczyk M, Zhu W, Woo AY, Morrell C, Poosala S, Xiao RP, Lakatta EG, Talan MI.

J Pharmacol Exp Ther. 2008 May;325(2):491-9. doi: 10.1124/jpet.107.135335. Epub 2008 Feb 20.

PMID:
18287209
20.

Intrahippocampal microinjection of an exquisitely low dose of ouabain mimics NaCl loading and stimulates a bufadienolide Na/K-ATPase inhibitor.

Fedorova OV, Zhuravin IA, Agalakova NI, Yamova LA, Talan MI, Lakatta EG, Bagrov AY.

J Hypertens. 2007 Sep;25(9):1834-44.

PMID:
17762648
21.

Therapeutic effectiveness of a single vs multiple doses of erythropoietin after experimental myocardial infarction in rats.

Moon C, Krawczyk M, Lakatta EG, Talan MI.

Cardiovasc Drugs Ther. 2006 Aug;20(4):245-51.

PMID:
17019537
23.

Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties.

Moon C, Krawczyk M, Paik D, Coleman T, Brines M, Juhaszova M, Sollott SJ, Lakatta EG, Talan MI.

J Pharmacol Exp Ther. 2006 Mar;316(3):999-1005. Epub 2005 Nov 23.

PMID:
16306273
24.

Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window.

Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI.

Cardiovasc Drugs Ther. 2005 Aug;19(4):243-50.

PMID:
16187008
25.

Brain ouabain stimulates peripheral marinobufagenin via angiotensin II signalling in NaCl-loaded Dahl-S rats.

Fedorova OV, Agalakova NI, Talan MI, Lakatta EG, Bagrov AY.

J Hypertens. 2005 Aug;23(8):1515-23.

PMID:
16003178
26.

Beneficial effects of chronic pharmacological manipulation of beta-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy.

Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, Talan MI.

Circulation. 2004 Aug 31;110(9):1083-90. Epub 2004 Aug 16.

PMID:
15313944
27.

Coordinated shifts in Na/K-ATPase isoforms and their endogenous ligands during cardiac hypertrophy and failure in NaCl-sensitive hypertension.

Fedorova OV, Talan MI, Agalakova NI, Lakatta EG, Bagrov AY.

J Hypertens. 2004 Feb;22(2):389-97.

PMID:
15076199
28.

Induction of myocardial infarcts of a predictable size and location by branch pattern probability-assisted coronary ligation in C57BL/6 mice.

Ahn D, Cheng L, Moon C, Spurgeon H, Lakatta EG, Talan MI.

Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1201-7.

29.

Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats.

Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI.

Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11612-7. Epub 2003 Sep 19.

30.

Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension.

Fedorova OV, Talan MI, Agalakova NI, Droy-Lefaix MT, Lakatta EG, Bagrov AY.

Hypertension. 2003 Mar;41(3):505-11. Epub 2003 Feb 10.

PMID:
12623951
31.

Endogenous ligand of alpha(1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride--dependent hypertension.

Fedorova OV, Talan MI, Agalakova NI, Lakatta EG, Bagrov AY.

Circulation. 2002 Mar 5;105(9):1122-7.

PMID:
11877366
32.

Cold acclimation-induced increase of systolic blood pressure in rats is associated with volume expansion.

Roukoyatkina NI, Chefer SI, Rifkind J, Ajmani R, Talan MI.

Am J Hypertens. 1999 Jan;12(1 Pt 1):54-62.

PMID:
10075385
33.
34.
35.

Central neural correlates of learned heart rate control during exercise: central command demystified.

Chefer SI, Talan MI, Engel BT.

J Appl Physiol (1985). 1997 Nov;83(5):1448-53.

36.

Metabolic costs of mounting an antigen-stimulated immune response in adult and aged C57BL/6J mice.

Demas GE, Chefer V, Talan MI, Nelson RJ.

Am J Physiol. 1997 Nov;273(5):R1631-7. doi: 10.1152/ajpregu.1997.273.5.R1631.

PMID:
9374803
37.
38.

Nonshivering thermogenesis in adult and aged C57BL/6J mice housed at 22 degrees C and at 29 degrees C.

Talan MI, Kirov SA, Kosheleva NA.

Exp Gerontol. 1996 Nov-Dec;31(6):687-98.

PMID:
9415097
39.
40.

Heat loss during cold exposure in adult and aged C57BL/6J mice.

Shefer VI, Talan MI, Engel BT.

Exp Gerontol. 1996 Sep-Oct;31(5):597-604.

PMID:
9415115
41.

Nonshivering thermogenesis during acute cold exposure in adult and aged C57BL/6J mice.

Kirov SA, Talan MI, Kosheleva NA, Engel BT.

Exp Gerontol. 1996 May-Jun;31(3):409-19.

PMID:
9415123
42.
43.

Overnight heart rate and cardiac function in patients with dual chamber pacemakers.

Chew PH, Bush DE, Engel BT, Talan MI, Abell RT.

Pacing Clin Electrophysiol. 1996 May;19(5):822-8. Erratum in: Pacing Clin Electrophysiol 1996 Aug;19(8):viii.

PMID:
8734750
44.

Sympathetic outflow to interscapular brown adipose tissue in cold acclimated mice.

Kirov SA, Talan MI, Engel BT.

Physiol Behav. 1996 Feb;59(2):231-5.

PMID:
8838599
45.

The effect of exercise training on cold tolerance in adult and old C57BL/6J mice.

Schaefer VI, Talan MI, Shechtman O.

J Gerontol A Biol Sci Med Sci. 1996 Jan;51(1):B38-42.

PMID:
8548498
46.

Effect of exercise on cold tolerance and metabolic heat production in adult and aged C57BL/6J mice.

Shechtman O, Talan MI.

J Appl Physiol (1985). 1994 Nov;77(5):2214-8.

PMID:
7868436
47.

Sympathetic nervous activity to brown adipose tissue increases in cold-tolerant mice.

Kawate R, Talan MI, Engel BT.

Physiol Behav. 1994 May;55(5):921-5.

PMID:
8022914
48.
49.
50.

Role of postural status in the nocturnal hemodynamic patterns of nonhuman primates.

Engel BT, Talan MI, Chew PH.

J Appl Physiol (1985). 1993 Apr;74(4):1684-8.

PMID:
8514683

Supplemental Content

Loading ...
Support Center